These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17125208)

  • 1. Pocket v.2: further developments on receptor-based pharmacophore modeling.
    Chen J; Lai L
    J Chem Inf Model; 2006; 46(6):2684-91. PubMed ID: 17125208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New features that improve the pharmacophore tools from Accelrys.
    Sutter J; Li J; Maynard AJ; Goupil A; Luu T; Nadassy K
    Curr Comput Aided Drug Des; 2011 Sep; 7(3):173-80. PubMed ID: 21726193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRID-based three-dimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation.
    Cross S; Baroni M; Goracci L; Cruciani G
    J Chem Inf Model; 2012 Oct; 52(10):2587-98. PubMed ID: 22970894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore-based virtual screening.
    Horvath D
    Methods Mol Biol; 2011; 672():261-98. PubMed ID: 20838973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fuzzy tricentric pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes.
    Bonachéra F; Parent B; Barbosa F; Froloff N; Horvath D
    J Chem Inf Model; 2006; 46(6):2457-77. PubMed ID: 17125187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of multiple binding modes of the CDK2 inhibitors, anilinopyrazoles, using the automated docking programs GOLD, FlexX, and LigandFit: an evaluation of performance.
    Sato H; Shewchuk LM; Tang J
    J Chem Inf Model; 2006; 46(6):2552-62. PubMed ID: 17125195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using pharmacophore models to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR.
    Toba S; Srinivasan J; Maynard AJ; Sutter J
    J Chem Inf Model; 2006; 46(2):728-35. PubMed ID: 16563003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU; Bembenek SD; Szalma S
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.
    Zou J; Xie HZ; Yang SY; Chen JJ; Ren JX; Wei YQ
    J Mol Graph Model; 2008 Nov; 27(4):430-8. PubMed ID: 18786843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-protein interface analysis and hot spots identification for chemical ligand design.
    Chen J; Ma X; Yuan Y; Pei J; Lai L
    Curr Pharm Des; 2014; 20(8):1192-200. PubMed ID: 23713772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of tautomer forms on pharmacophore-based virtual screening.
    Oellien F; Cramer J; Beyer C; Ihlenfeldt WD; Selzer PM
    J Chem Inf Model; 2006; 46(6):2342-54. PubMed ID: 17125178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular structural characteristics of estrogen receptor modulators as determinants of estrogen receptor selectivity.
    Agatonovic-Kustrin S; Turner JV
    Mini Rev Med Chem; 2008 Aug; 8(9):943-51. PubMed ID: 18691152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors.
    Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():47-58. PubMed ID: 26231707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extensive and diverse set of molecular overlays for the validation of pharmacophore programs.
    Giangreco I; Cosgrove DA; Packer MJ
    J Chem Inf Model; 2013 Apr; 53(4):852-66. PubMed ID: 23565904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecule-pharmacophore superpositioning and pattern matching in computational drug design.
    Wolber G; Seidel T; Bendix F; Langer T
    Drug Discov Today; 2008 Jan; 13(1-2):23-9. PubMed ID: 18190860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The conformational musings of a medicinal chemist.
    Finch H
    Drug Discov Today; 2014 Mar; 19(3):320-5. PubMed ID: 24184532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.
    Carlson KE; Choi I; Gee A; Katzenellenbogen BS; Katzenellenbogen JA
    Biochemistry; 1997 Dec; 36(48):14897-905. PubMed ID: 9398213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-dependent conformation change reflects steric structure and interactions of a vitamin D receptor/ligand complex: a fragment molecular orbital study.
    Motoyoshi S; Yamagishi K; Yamada S; Tokiwa H
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):56-9. PubMed ID: 20236615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.